Related Experiment Videos
Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line
Abstract:
In view of a potential clinical use, we assessed the antiproliferative effect of paclitaxel on the human steroid-secreting NCI-H295 adrenocarcinoma cell line. By MTT, paclitaxel induced a dose-dependent inhibition of cell proliferation, with IC50 lower than blood levels of the drug achieved in patients treated for other malignancies. Cell exposure to paclitaxel for 24 h at the different IC50S produced a dose-responsive increase in DNA fragmentation, morphologically confirmed by electron microscopy. A time-dependent decrease in aldosterone, cortisol and testosterone was observed. Paclitaxel is an effective antiproliferative agent in this human adrenocortical carcinoma cell line. Apoptosis induced by the drug in involved in neoplastic cell death. A potential role of the drug in the treatment of patients with adrenocortical cancer could be considered.
Insights
Paclitaxel effectively inhibits proliferation and induces apoptosis in human adrenocortical cancer cells. This suggests paclitaxel may be a potential treatment for adrenocortical carcinoma.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Adrenocortical carcinoma is a rare but aggressive endocrine malignancy.
- Limited effective systemic therapies exist for advanced adrenocortical carcinoma.
- Paclitaxel is a chemotherapy agent with known antiproliferative properties.
Purpose of the Study:
- To evaluate the antiproliferative effects of paclitaxel on a human adrenocortical carcinoma cell line (NCI-H295).
- To investigate the mechanism of cell death induced by paclitaxel in this cell line.
- To assess the potential clinical utility of paclitaxel in treating adrenocortical cancer.
Main Methods:
- MTT assay to determine dose-dependent inhibition of cell proliferation.
- Electron microscopy to confirm morphological changes indicative of apoptosis.
- Measurement of steroid hormone levels (aldosterone, cortisol, testosterone) following paclitaxel treatment.
Main Results:
- Paclitaxel demonstrated a dose-dependent antiproliferative effect on NCI-H295 cells.
- The inhibitory concentration 50 (IC50) values were below clinically achievable blood levels.
- Paclitaxel induced DNA fragmentation and apoptosis, leading to neoplastic cell death.
- A time-dependent decrease in aldosterone, cortisol, and testosterone secretion was observed.
Conclusions:
- Paclitaxel exhibits significant antiproliferative activity against human adrenocortical carcinoma cells.
- Apoptosis is a key mechanism by which paclitaxel mediates cancer cell death.
- Paclitaxel warrants consideration as a potential therapeutic agent for patients with adrenocortical cancer.